Drug intelligence / Profile preview

ABI-220

Development stage: Preclinical
Lead developer: Avirmax Biopharma
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intravitreal

Overview

ABI-220 is a preclinical-stage AAV-based gene therapy being developed by Avirmax Biopharma for the treatment of dry age-related macular degeneration (dry AMD). The therapy utilizes Avirmax's proprietary engineered AAV capsids, specifically the AAV.OFM platform, which is optimized for efficient retinal transduction following intravitreal injection. By delivering a therapeutic transgene directly to the retina, ABI-220 aims to address the underlying causes of geographic atrophy and vision loss associated with dry AMD. As of 2024, the program remains in preclinical development, focusing on establishing safety and efficacy in relevant models before advancing to clinical trials.

Beyond the preview

Go deeper on ABI-220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABI-220.

Explore the full profile